左侧心脏瓣膜术后新发房颤的长期血栓栓塞风险
该观察性队列研究基于丹麦全国登记数据,纳入2000至2015年孤立左侧心脏瓣膜术后新发术后房颤(POAF)患者,并按1:3匹配非手术非瓣膜性房颤(NVAF)患者。匹配后POAF 675例、NVAF 2025例,中位年龄71岁,59.3%为男性。调整分析显示POAF与NVAF长期血栓栓塞风险相似(HR 1.22,95%CI 0.88-1.68),随访期口服抗凝与两类患者血栓栓塞风险降低相关。
要点
- 左侧瓣膜术后新发POAF的长期血栓栓塞风险与NVAF相似(HR 1.22,95%CI 0.88-1.68)。
- POAF患者随访期口服抗凝与血栓栓塞风险降低相关(HR 0.45,95%CI 0.22-0.90)。
- NVAF患者随访期口服抗凝亦与血栓栓塞风险降低相关(HR 0.63,95%CI 0.45-0.87)。
核心结论
- 孤立左侧心脏瓣膜术后新发POAF的长期血栓栓塞风险与NVAF相似。
- 研究提示需进一步探讨左侧瓣膜术后POAF的抗凝治疗作用。
研究设计与样本
- 观察性队列研究,使用丹麦全国登记和东丹麦心脏手术数据库,时间2000年1月1日至2015年12月31日。
- 纳入2000至2015年孤立左侧心脏瓣膜手术(生物瓣主动脉瓣或二尖瓣置换和/或主动脉瓣或二尖瓣修复)后发生POAF的患者。
- POAF患者按1:3匹配非手术NVAF患者,匹配因素包括年龄、性别、心力衰竭、高血压、糖尿病、血栓栓塞史、缺血性心脏病和诊断年份。
- 匹配后研究人群为POAF 675例和NVAF 2025例,中位年龄71(四分位距65-77)岁,1600例(59.3%)为男性。
主要发现
- 1587例孤立左侧心脏瓣膜手术患者中,741例(46.7%)在住院期间发生POAF。
- 712例POAF患者符合匹配条件,其中675例成功匹配2025例NVAF患者。
- POAF患者出院后30天内启动口服抗凝420例(62.9%),NVAF患者1030例(51.4%)。
- POAF和NVAF的粗血栓栓塞发生率分别为21.9(95%CI 17.4-27.6)和17.7(95%CI 15.2-20.6)事件/1000人年。
- 调整分析中,POAF与NVAF的长期血栓栓塞风险相似(HR 1.22,95%CI 0.88-1.68)。
临床怎么用
- 左侧心脏瓣膜术后新发POAF患者应被视为长期血栓栓塞高风险人群,风险程度与NVAF相当。
- 随访期口服抗凝可能降低POAF患者血栓栓塞风险,但需进一步研究明确抗凝策略。
局限性
- 原文未系统列出局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: New-onset postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. However, data on the long-term risk of thromboembolism in patients who develop POAF after heart valve surgery are conflicting. In addition, data on stroke prophylaxis in this setting are lacking. OBJECTIVE: To assess the long-term risk of thromboembolism in patients developing new-onset POAF after isolated left-sided heart valve surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study was conducted from January 1, 2000, through December 31, 2015, using Danish nationwide registries and the Eastern Danish Heart Surgery Database. Patients who developed POAF after isolated left-sided heart valve surgery (bioprosthetic aortic or mitral valve replacement and/or aortic or mitral valve repair) from 2000 through 2015 were included. These patients were matched with patients with nonsurgical NVAF in a 1:3 ratio by age, sex, heart failure, hypertension, diabetes, a history of thromboembolism, ischemic heart disease, and year of diagnosis. Data analyses took place from January to March 2019. MAIN OUTCOMES AND MEASURES: Rates of thromboembolism. RESULTS: Of the 1587 patients who underwent isolated left-sided heart valve surgery, 741 patients (46.7%) developed POAF during admission. Of the 712 patients with POAF who were eligible for matching, 675 patients were matched with 2025 patients with NVAF and made up the study population. In the matched study population, the median age was 71 (interquartile range, 65-77) years, and 1600 (59.3%) were men. Oral anticoagulation therapy was initiated within 30 days postdischarge in 420 patients with POAF (62.9%) and in 1030 patients with NVAF (51.4%). The crude incidence rates of thromboembolism were 21.9 (95% CI, 17.4-27.6) and 17.7 (95% CI, 15.2-20.6) events per 1000 person-years for patients with POAF and patients with NVAF, respectively. In the adjusted analysis, the long-term risk of thromboembolism was similar in patients with POAF and NVAF (hazard ratio, 1.22 [95% CI, 0.88-1.68]). Oral anticoagulation therapy during follow-up was associated with a lower risk of thromboembolic events in patients with POAF (hazard ratio, 0.45 [95% CI, 0.22-0.90]) as well as patients with NVAF (hazard ratio, 0.63 [95% CI, 0.45-0.87]) compared with no anticoagulation therapy. CONCLUSIONS AND RELEVANCE: New-onset POAF after isolated left-sided heart valve surgery was associated with a similar long-term risk of thromboembolism as NVAF. These data warrant studies addressing the role of anticoagulation therapy in POAF after left-sided heart valve surgery.
引用
- Butt JH, Olesen JB, Gundlund A, et al. Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery. JAMA Cardiol. 2019. PMID: 31596426. doi:10.1001/jamacardio.2019.3649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。